Cooper Companies (NASDAQ:COO) Given New $116.00 Price Target at Citigroup

Cooper Companies (NASDAQ:COO) had its price target upped by Citigroup from $108.00 to $116.00 in a report released on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the medical device company’s stock.

COO has been the topic of a number of other research reports. Piper Sandler boosted their price objective on Cooper Companies from $110.00 to $115.00 and gave the stock an overweight rating in a research note on Friday, March 1st. KeyCorp began coverage on Cooper Companies in a report on Tuesday, February 6th. They issued a sector weight rating for the company. Stifel Nicolaus reissued a buy rating and set a $110.00 target price (up from $105.00) on shares of Cooper Companies in a research report on Friday, March 1st. TheStreet lowered shares of Cooper Companies from a b- rating to a c rating in a report on Thursday, February 29th. Finally, JPMorgan Chase & Co. raised shares of Cooper Companies from a neutral rating to an overweight rating and lifted their price target for the stock from $100.00 to $120.00 in a research note on Wednesday, March 13th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus price target of $109.48.

Cooper Companies Stock Performance

Shares of COO stock opened at $98.96 on Wednesday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.08 and a current ratio of 1.86. The firm has a market capitalization of $19.67 billion, a price-to-earnings ratio of 67.66, a price-to-earnings-growth ratio of 2.52 and a beta of 0.94. Cooper Companies has a one year low of $75.93 and a one year high of $104.07. The company has a 50 day moving average price of $97.59 and a 200 day moving average price of $89.97.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Thursday, February 29th. The medical device company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.07. Cooper Companies had a return on equity of 8.79% and a net margin of 7.93%. The business had revenue of $931.60 million during the quarter, compared to the consensus estimate of $915.93 million. During the same period in the prior year, the firm posted $2.90 EPS. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. Sell-side analysts anticipate that Cooper Companies will post 3.5 EPS for the current year.

Insider Transactions at Cooper Companies

In other Cooper Companies news, CAO Agostino Ricupati sold 54,724 shares of the stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $100.89, for a total transaction of $5,521,104.36. Following the transaction, the chief accounting officer now owns 5,081 shares of the company’s stock, valued at approximately $512,622.09. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Gary S. Petersmeyer sold 1,000 shares of Cooper Companies stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $103.51, for a total value of $103,510.00. Following the completion of the transaction, the director now directly owns 5,668 shares of the company’s stock, valued at approximately $586,694.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Agostino Ricupati sold 54,724 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $100.89, for a total transaction of $5,521,104.36. Following the sale, the chief accounting officer now owns 5,081 shares in the company, valued at approximately $512,622.09. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On Cooper Companies

Several institutional investors have recently made changes to their positions in the stock. Symmetry Partners LLC increased its position in Cooper Companies by 300.0% in the first quarter. Symmetry Partners LLC now owns 2,800 shares of the medical device company’s stock worth $284,000 after buying an additional 2,100 shares during the period. Canandaigua National Bank & Trust Co. grew its position in shares of Cooper Companies by 293.4% during the first quarter. Canandaigua National Bank & Trust Co. now owns 2,844 shares of the medical device company’s stock worth $289,000 after acquiring an additional 2,121 shares during the last quarter. Nomura Holdings Inc. acquired a new stake in shares of Cooper Companies in the 4th quarter worth about $373,000. HighPoint Advisor Group LLC bought a new stake in Cooper Companies in the 4th quarter valued at about $1,964,000. Finally, PNC Financial Services Group Inc. boosted its stake in Cooper Companies by 1.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 21,385 shares of the medical device company’s stock valued at $8,093,000 after purchasing an additional 346 shares during the period. 24.39% of the stock is owned by institutional investors.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.